Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00336388
Other study ID # CDC-NCID-4701
Secondary ID
Status Completed
Phase N/A
First received June 10, 2006
Last updated March 8, 2010
Start date July 2006
Est. completion date September 2006

Study information

Verified date March 2010
Source Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentKenya: Kenya Medical Research Institute
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the impact of rapid diagnostic tests (RDTs) in the context of a newly implemented malaria case management guidelines using artemisinin-based combination therapy on the malaria prescribing practices of health care workers in Kenya.


Description:

Malaria causes an estimated 300-500 million infections and over 1 million deaths per year, predominantly in children <5 years old in sub-Saharan Africa. In most parts of malaria endemic sub-Saharan Africa, clinical or presumptive diagnosis, often based on the presence of fever, is the primary means of diagnosing malaria. Clinical diagnosis is sensitive but poorly specific, leading to substantial over-diagnosis. Personnel and supplies to perform microscopic examination of blood smears of persons suspected of having malaria (the current gold standard for diagnosis of malaria) are not available at most health facilities. Over-diagnosis and subsequent over-treatment of patients as a result of clinical diagnosis can lead to increased drug pressure that may facilitate the development of drug resistance in P. falciparum, the malaria parasite responsible for most associated morbidity and mortality in sub-Saharan Africa. This may also increase costs, particularly with the shift from inexpensive antimalarials (such as chloroquine and sulfadoxine-pyrimethamine) to newer, more expensive artemisinin-based combination therapies (ACTs) (such as artemether plus lumefantrine, also known as Coartem®). Over-diagnosis also exposes patients to the unnecessary risk of adverse drug events and, among some patients, leaves the real cause of illness untreated.

Rapid diagnostic tests (RDTs) use immunochromatographic methods to detect antigens derived from malaria parasites in lysed blood. RDTs have generally been reported to achieve field sensitivities and specificities of >90% in the detection of Plasmodium falciparum at densities above 100 parasites/μL blood. RDTs are easy to use and interpret, do not require electricity or special equipment, and can be shipped and stored at ambient conditions.

We hypothesize the use of RDTs should improve malaria diagnosis compared to the use of clinical diagnosis alone. Having access to a test that quickly confirms or excludes the presence of malaria parasites will enable the health care worker (HCW) to determine whether antimalarials are appropriate. If test results are used in this manner, the number of unneeded antimalarial prescriptions should diminish, thus reducing the potential for the development of drug resistance. However, whether and how HCWs will actually use RDT results is unknown. Prior research has demonstrated that results of microscopy are often ignored, and that HCWs often rely on their clinical impressions to diagnose malaria and prescribe treatment.

This study seeks to the describe behaviors and perceptions associated with the use of RDTs for diagnosis of malaria among patients >5 years of age at health facilities in Bondo and Kericho Districts of Kenya, areas of low and high malaria transmission. The specific objectives are:

1. To evaluate the impact of RDTs introduced in the context of newly implemented malaria case management guidelines using ACTs compared to new malaria case management guidelines using ACTs and clinical diagnosis on malaria diagnosis and prescribing practices by HCWs caring for patients >5 years of age.

2. To evaluate HCW performance and adherence to the newly implemented guidelines and use of RDTs.

3. To analyze the costs to a health facility of treating a patient with a fever with two management strategies (RDTs + ACTs compared to clinical diagnosis + ACTs) if treatment guidelines are correctly followed and based on actual HCW adherence to the new guidelines.

4. To evaluate the sensitivity and specificity of RDTs in the hands of HCWs at health facilities in Kenya compared to expert microscopy and compared to RDTs performance in hands of trained study laboratory technicians.

5. To evaluate factors influencing the acceptability of RDTs by HCWs.

6. To evaluate factors influencing the acceptability of RDTs by patients.

7. To evaluate the programmatic implications of RDT introduction.

This trial will generate important public health information regarding the use of RDTs in malaria case management. The study findings will be used to guide provider training, the development of community Information, Education and Communication strategies, and other interventions. These data will be valuable to other countries in sub-Saharan Africa preparing for the introduction of new drug treatment policies and considering methods to improve malaria diagnosis.


Recruitment information / eligibility

Status Completed
Enrollment 3600
Est. completion date September 2006
Est. primary completion date September 2006
Accepts healthy volunteers No
Gender Both
Age group 5 Years and older
Eligibility Inclusion Criteria:

- All ill persons >5 years old attending health facilities in Bondo and Kericho Districts, Kenya

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
Paracheck Device


Locations

Country Name City State
Kenya Bondo and Kericho District Health Facilities Kisumu Nyanza Province

Sponsors (4)

Lead Sponsor Collaborator
Centers for Disease Control and Prevention KEMRI-Wellcome Trust Collaborative Research Program, Kenya Division of Malaria Control, Kenya Medical Research Institute

Country where clinical trial is conducted

Kenya, 

References & Publications (1)

Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002 Jan;15(1):66-78. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and specificity of malaria diagnosis 6 weeks after the introduction of malaria rapid diagnostic tests
Secondary Adherence to malaria case management guidelines by health care workers
Secondary Cost effectiveness of malaria case management guidelines using malaria rapid diagnostic tests
Secondary Acceptability of malaria rapid diagnostic tests to health care workers
Secondary Acceptability of malaria rapid diagnostic tests to patients
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02536222 - Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Phase 4